Imperative Care Announces Positive Real-World Data Showing that the Zoom Stroke Solution Achieved Superior Procedure Outcomes with Lower Cost in Ischemic Stroke Patients

Preliminary Data Presented at the Society of NeuroInterventional Surgery Annual Meeting Highlight Benefits of Zoom for Mechanical Thrombectomy

Imperative Care, Inc. today announced that new data from studies evaluating the utility of the Zoom Stroke Solution were presented at the Society of NeuroInterventional Surgery (SNIS) 2022 19th Annual Meeting in Toronto.

“At Imperative Care, we know that clinical data are foundational to validating medical technologies and improving patient outcomes,” said Daniel Davis, president and COO of Imperative Care. “The results from these studies are a meaningful step forward in ongoing efforts to collect real-world evidence on the safety and efficacy of our technologies, and we look forward to continuing our clinical progress in collaboration with the neurointerventional community.”

Results from an independent single center experience evaluating the association between guide catheter position and final reperfusion in patients who received aspiration thrombectomy for ischemic stroke were presented by James Milburn, M.D., Ochsner Health, New Orleans, Louisiana.

Findings from the study demonstrated that intracranial guide catheter placement in the petrous internal carotid artery (ICA) segment or further distal versus placement in the cervical ICA segment or more proximal was associated with a better rate of TICI≥2C reperfusion (82.7% compared to 60%, p=0.019, respectively), and a better first-pass effect (51.9% compared to 27.5%, p=0.021, respectively). Access time to final recanalization was significantly shorter in patients with intracranial guide catheter placement (23.8 minutes) compared to patients with proximal guide catheter placement (33.9 minutes), p=0.011.

“The introduction of large bore guide catheters that can track further in the brain has been a game-changer for the treatment of ischemic stroke,” said Dr. Milburn. “These results further support that intracranial access is directly associated with improved reperfusion, or as evidenced by this study, final TICI 2C or better reperfusion rate. The Zoom 88 Large Distal Platform has become my default guide catheter for stroke. Going further up into brain and closer to the clot with Zoom 88 results in enhanced navigation support and improves first pass effect by losing clot less frequently and achieving quicker access in patients suffering emergent large vessel occlusions.”

Results from a study evaluating the effect of intracranial flow parameters using various guide catheters for aspiration thrombectomy were presented by Holly Berns, Ph.D. candidate, Northern Arizona University. The study showed an 67% flow reduction in the MCA when a Zoom 88 access catheter was positioned distal to the posterior communicating artery and proximal to the carotid terminus. This flow reduction was significantly greater when compared to the 54% reduction achieved with an inflated balloon guide catheter positioned in the proximal ICA. In comparison, the study found that placing a long sheath in the proximal ICA resulted in approximately 30% flow reduction in the MCA, or less than half the flow reduction achieved with Zoom 88 at the carotid terminus.

“Significantly reduced flow locally at the thrombus location can meaningfully reduce potential downstream migration during mechanical thrombectomy,” said senior author of the study, Timothy A. Becker, Ph.D., Northern Arizona University. “The findings from this study demonstrate that distal placement of a Zoom 88 can translate to better flow reduction than a balloon guide catheter without substantial reduction to collateral or ipsilateral flow and the additional time required to set up the balloon placed proximally.”

One additional single center report on the Zoom Stroke Solution was presented by Dr. Milburn at the meeting, which evaluated an aspiration first approach using Zoom catheters in patients with ICA, M1 and M2 occlusions. The study found that the use of angled tip aspiration catheters for thrombectomy was associated with quicker time to final reperfusion, lower use of stent retrievers, and lower use of additional aspiration catheters, suggesting a reduction in procedure cost.

Additionally, data from a multi-center retrospective review of 58 consecutive patients who underwent venous sinus stenting for idiopathic intracranial hypertension were presented by Shahid Nimjee, M.D., Ph.D., The Ohio State University Wexner Medical Center. In this report, Imperative Care’s TracStar LDP technology was used to provide access to intracranial vasculature and was advanced to the location of the stent placement in 97.9% of cases. Results from the study indicated that TracStar LDP is a safe and effective access platform for patients with idiopathic intracranial hypertension who are candidates for stent placement. Authors of the study suggested that the high rate of technical success in accessing the pathology may be attributed to the unique design elements of the TracStar LDP, which combines the flexibility of a distal access catheter with the support of a long sheath in a single large .088” intracranial access catheter.

About the Zoom Stroke Solution

The Zoom Stroke Solution is the complete stroke system from access through reperfusion for fast and effective clot removal for patients with acute ischemic stroke. The system includes the Zoom 88 Large Distal Platform for neurovascular access, four vessel-matched Zoom Aspiration Catheters, the Zoom Pump, the Zoom POD and other accessories. All Zoom catheters are designed with the TRX™ Tip which provides 15% greater clot engagement area at the tip of the catheter and are designed to enable smooth tracking through challenging vasculature. For complete product information, including indications, contraindications, warnings, precautions and adverse events visit: http://bit.ly/2Vx0Qcf

About Imperative Care, Inc.

Imperative Care is a medical technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke. The company has two 510(k) cleared product platforms, as well as an expansive stroke technology development pipeline. In addition, Imperative Care’s wholly owned subsidiary Truvic is developing solutions for the treatment of peripheral vascular disease. Imperative Care and Truvic are based in Campbell, Calif. https://imperativecare.com

+ Dr. Milburn is a paid consultant for Imperative Care.

+ The Northern Arizona University study was sponsored by Imperative Care.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005064/en/